tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
John Deakin-Bell

John Deakin-Bell

Citigroup
Wall Street Analyst
Ranked #3,894 out of 8,047 Analysts on TipRanks (#8,500 out of 21,521 overall experts)

Success Rate

66%
49 out of 74 Profitable Transactions

Average Return

1.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied John Deakin-Bell's ratings since 2021 and opened each position for the duration of 1 Year:
66.22% of your transactions would have been profitable with an average return of 1.4%

Stock Rating Distribution

242Ratings
45.04% Hold
40.91% Buy
14.05% Sell
Distribution of John Deakin-Bell's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
AustraliaAustralian Market

Best Rating

Stock:
CSL Limited
(CMXHF)
Rating Type:Buy
Dates:Feb 13, 2019 - Dec 05, 2019
Gain:45.80%
The most profitable rating made by John Deakin-Bell

John Deakin-Bell's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Sonic Healthcare
Hold
Downgraded
100%
+17.80%
4
Hold
Downgraded
100%
+15.90%
4
Australian Pharmaceutical Industries Ltd
Hold
Reiterated
0.00%
5
Ansell
Buy
Reiterated
$26.01
(48.98% Upside)
36%
-6.79%
20
Pro Medicus Limited
Hold
Upgraded
100%
+23.00%
2
Sigma Healthcare Ltd
Hold
Reiterated
0.00%
1
Sonic Healthcare Limited
Hold
Reiterated
A$39.00
(16.28% Upside)
0.00%
18
Cochlear Limited
Buy
Reiterated
$167.48
(11.19% Upside)
67%
+4.75%
27
Fisher & Paykel Healthcare Corporation Limited
Buy
Upgraded
70%
-17.33%
13
Healius Limited
Buy
Upgraded
0.00%
22
List of latest recommendations made by John Deakin-Bell. Click to expand and see John Deakin-Bell's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More